The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
More than 40 types of Amyloid proteins are discovered till date
The company will present 21 oral and poster presentations spanning investigational and approved therapies
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
Final decision from the European Commission is anticipated within the coming months
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
US FDA approval based on NEURO-TTRansform Phase III results
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
